MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
NCT03072407
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Type2 Diabetes Mellitus
Interventions
BIOLOGICAL:
PB-119 injection
BIOLOGICAL:
PB-119 injection placebo
Sponsor
PegBio Co., Ltd.